QuanBio Appoints Aubrey C. Galloway, MD, as Chief Medical Officer

QuanBio has appointed Aubrey C. Galloway, MD, as its Chief Medical Officer (CMO).14

The announcement was made in early January 2026 and is listed in industry people news for January 7, 2026.24

QuanBio is described as an AI‑driven vascular intelligence cardiothoracic company, indicating a focus on applying artificial intelligence to vascular and cardiothoracic care.1

As CMO, Dr. Galloway will oversee QuanBio’s clinical strategy and medical affairs, supporting development and deployment of its vascular intelligence technologies.14

Dr. Galloway is a cardiothoracic surgeon with extensive clinical and leadership experience, which QuanBio highlights as central to guiding its clinical programs.14

The company positions this appointment as a key step to advance its mission of improving outcomes in vascular and cardiothoracic disease using AI‑enabled solutions.14

Sources:

1. https://firstwordpharma.com/story/7047975

2. https://firstwordpharma.com/river/type/People%20News

4. https://www.einpresswire.com/channel/healthcare-pharmaceuticals